Topeka Capital Starts D.R. Horton (DHI) at Hold
Get Alerts DHI Hot Sheet
Price: $148.81 -0.71%
Rating Summary:
13 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
13 Buy, 23 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Topeka Capital initiates coverage on D.R. Horton (NYSE: DHI) with a Hold. PT $18.00.
The firm comments, "Year-to-date, D.R. Horton's share price is up approximately 50.0% versus an average 110.0% return for the rest of our homebuilder coverage and a 12.1% return for the S&P 500. If the fiscal cliff, QM, and QRM are resolved favorably for housing demand, we believe our concerns about entry-level buyers (approximately 50.0% of DHI's customers) access to mortgage financing would be resolved. At current levels, we believe this positive headline risk is reflected, and we would stay to the side."
For an analyst ratings summary and ratings history on D.R. Horton click here. For more ratings news on D.R. Horton click here.
Shares of D.R. Horton closed at $18.69 yesterday.
The firm comments, "Year-to-date, D.R. Horton's share price is up approximately 50.0% versus an average 110.0% return for the rest of our homebuilder coverage and a 12.1% return for the S&P 500. If the fiscal cliff, QM, and QRM are resolved favorably for housing demand, we believe our concerns about entry-level buyers (approximately 50.0% of DHI's customers) access to mortgage financing would be resolved. At current levels, we believe this positive headline risk is reflected, and we would stay to the side."
For an analyst ratings summary and ratings history on D.R. Horton click here. For more ratings news on D.R. Horton click here.
Shares of D.R. Horton closed at $18.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berkshire adds significantly to Alphabet position, starts small position in DR Horton
- BTIG homebuilder survey shows July sales decline amid rate surge
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share